User profiles for Calen A. Steiner
 | Calen A SteinerAssistant Professor, Gastroenterology, University of Colorado Verified email at cuanschutz.edu Cited by 972 |
Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis
OBJECTIVES: Irritable bowel syndrome (IBS) is a common gastrointestinal condition with a
heterogeneous pathophysiology. An altered gut microbiome has been identified in some IBS …
heterogeneous pathophysiology. An altered gut microbiome has been identified in some IBS …
Structural correlates of apathy in Alzheimer's disease
…, GG Akopyan, N Partiali, CA Steiner… - Dementia and geriatric …, 2007 - karger.com
Background: Apathy is the most common noncognitive symptom inAlzheimer’s disease (AD).
The structural correlates of apathy in AD have not yet been described. Methods: We …
The structural correlates of apathy in AD have not yet been described. Methods: We …
Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study
…, JL Sheehan, M Dias, EM Berinstein, CA Steiner… - Clinical …, 2021 - Elsevier
Background & Aims Despite rescue therapy, more than 30% of patients with acute severe
ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting Janus kinase …
ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting Janus kinase …
Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease
LG Apostolova, CA Steiner, GG Akopyan… - Archives of …, 2007 - jamanetwork.com
Background Alzheimer disease (AD) is the most common form of dementia worldwide.Mild
cognitive impairment(MCI) is the recent terminology for patients with cognitive deficiencies in …
cognitive impairment(MCI) is the recent terminology for patients with cognitive deficiencies in …
Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis
JA Berinstein, CA Steiner, RE Regal… - Clinical …, 2019 - cghjournal.org
Methods All 4 patients with ASUC had a high likelihood of failing IV corticosteroid monotherapy
based on severe Truelove and Witt’s criteria, C-reactive protein (CRP)> 100 mg/L at …
based on severe Truelove and Witt’s criteria, C-reactive protein (CRP)> 100 mg/L at …
Hypoxia-inducible factor as a bridge between healthy barrier function, wound healing, and fibrosis
The healthy mammalian intestine is lined by a single layer of epithelial cells. These cells
provide a selectively permeable barrier to luminal contents and normally do so in an efficient …
provide a selectively permeable barrier to luminal contents and normally do so in an efficient …
Biomarkers for the prediction and diagnosis of fibrostenosing Crohn's disease: a systematic review
CA Steiner, JA Berinstein, J Louissaint… - Clinical …, 2022 - Elsevier
Background and Aims Intestinal strictures are a common complication of Crohn’s disease (CD).
Biomarkers of intestinal strictures would assist in their prediction, diagnosis, and …
Biomarkers of intestinal strictures would assist in their prediction, diagnosis, and …
[HTML][HTML] Hepatic steatosis is associated with increased disease severity and liver injury in coronavirus disease-19
…, I Kassab, KD Platt, CY Hsu, CA Steiner… - Digestive diseases and …, 2021 - Springer
Background Coronavirus disease-2019 (COVID-19) is a global pandemic. Obesity has been
associated with increased disease severity in COVID-19, and obesity is strongly associated …
associated with increased disease severity in COVID-19, and obesity is strongly associated …
[HTML][HTML] Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature
EM Berinstein, JL Sheehan, J Jacob, CA Steiner… - Digestive Diseases and …, 2023 - Springer
Background Dual targeted therapy (DTT) has emerged as an attractive therapeutic option
for select patients with active inflammatory bowel disease (IBD) who are unable to achieve …
for select patients with active inflammatory bowel disease (IBD) who are unable to achieve …
AXL is a potential target for the treatment of intestinal fibrosis
CA Steiner, ES Rodansky, LA Johnson… - Inflammatory bowel …, 2021 - academic.oup.com
Background Fibrosis is the final common pathway to intestinal failure in Crohn’s disease,
but no medical therapies exist to treat intestinal fibrosis. Activated myofibroblasts are key …
but no medical therapies exist to treat intestinal fibrosis. Activated myofibroblasts are key …